Idiopathic pulmonary fibrosis: state of the art for 2023
The DOI matches its Crossref record; 188 of the 196 references it cites were found in a registry or an index.
Abstract
Review noting that IPF is a progressive fibrotic lung disease characterized by worsening respiratory symptoms and physiological impairment, while the individual patient course and rate of disease progression are often unpredictable and heterogeneous.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to now, the specific therapeutic drugs that reverse IPF or halt the progression of IPF are still unavailable due to the incomplete understanding of the pathogenesis of IPF 5.”
From Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice (2024) · cites this paper as [5]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation
Research works printed but not linked: 1
- 10.1186/s12931-019 · doi:10.1186/s12931-019
Cited by
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
“Median survival time is 3–5 years after diagnosis without treatment [2], but recently published observations report improving survival over the last 2 decades, may be related to earlier diagnosis, and use of antifi-brotics [3, 4].”
BackgroundPulmonary fibrosis: pathogenesis and therapeutic strategies
Wang, J., Li, K., Hao, D., Li, X., Zhu, Y., Yu, H., & Chen, H. (2024) · MedComm · doi:10.1002/mco2.744 · Cited by 150
Spatial transcriptomic characterization of pathologic niches in IPF
Mayr, C. H., Santacruz, D., Jarosch, S., Bleck, M., Dalton, J., McNabola, A., Lempp, C., Neubert, L., Rath, B., Kamp, J. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl5473 · Cited by 147
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, M. I., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060709 · Cited by 128
“…distortion may ultimately impact up to eleven percent of patients after hospitalization with COVID-19, support the need for validated treatment protocols to contrast the progression of lung alterations and the emerging consequences of the pandemic, especially in younger patients [61,99,100].”
BackgroundRaghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 92
Self-citationPamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
Raghu, G., Richeldi, L., Pérez, E. R. F., Salvo, M. C. D., Silva, R. S., Song, J. W., Ogura, T., Xu, Z., Belloli, E. A., Zhang, X., et al. (2024) · JAMA · doi:10.1001/jama.2024.8693 · Cited by 104
Self-citationBhat, A. A., Afzal, M., Goyal, A., Gupta, G., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Shahwan, M. J., Paudel, K. R., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111002 · Cited by 90
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 124
Hu, Y., Huang, Y., Zong, L., Lin, J., Liu, X., & Ning, S. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02078-0 · Cited by 89
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Chen, Y., Wang, T., Liang, F., Han, J., Lou, Z., Yu, Y., Li, J., Zhan, T., Gu, Y., Dong, L., et al. (2024) · Theranostics · doi:10.7150/thno.94482 · Cited by 60
Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes
Humphries, S. M., Thieke, D., Baraghoshi, D., Strand, M. J., Swigris, J. J., Chae, K. J., Hwang, H. J., Oh, A. S., Flaherty, K. R., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1191oc · Cited by 62
Bao, H., Wu, M., Xing, J., Li, Z., Zhang, Y., Wu, A., & Li, J. (2024) · Science Advances · doi:10.1126/sciadv.adq0703 · Cited by 51
Animal models of acute exacerbation of pulmonary fibrosis
Xu, Y., Zhang, M., Gu, H., Liu, M., Zhao, Y., Shi, Y., Wu, S., Jiang, C., Ye, X., Zhu, H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02595-z · Cited by 43
“This condition leads to a decline in physiological function, severe respiratory symptoms, and ultimately fatal clinical outcomes [2–4].”
BackgroundIdiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
Self-citationRusso, R. C., & Ryffel, B. (2024) · Cells · doi:10.3390/cells13242058 · Cited by 39
“Although Pirfenidone and Nintedanib are currently approved for treating idiopathic PF (IPF), patients still have high mortality rates and a median survival duration of only 3–5 years [98–101].”
Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis
Chen, Z., Yang, J., Zhang, Q., Zeng, W., Liu, Y., Hu, W., Chen, L., Shen, J., Miao, Y., Xiao, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv9571 · Cited by 36
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
“Therapeutic options for these diseases are limited and may be tolerated poorly by patients [16, 17].”
BackgroundSelf-citationInhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., Salvo, M. D., Wuyts, W. A., Gallegos, J. P., Song, J. M., Kramer, M. R., King, C., Mackintosh, J. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512911 · Cited by 54
Liu, Z., Peng, Z., Lin, H., Zhou, K., Liang, L., Cao, J., Huang, Z., & Mei, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02848-5 · Cited by 34
“In the past two decades, the incidence of IPF has increased, especially among the elderly [2].”
BackgroundPARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation
Zhu, X., Huo, Q., Jin, L., Du, J., Yu, J., Wang, H., Wu, N., Li, Y., Rui, Y., Zhao, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady1681 · Cited by 36
Macisaac, S., Somboonviboon, D., Scallan, C. J., & Kolb, M. R. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2340723 · Cited by 28
“Unfortunately, there are only two approved anti-fibrotic medications for treatment of IPF both of which slow the rate of decline but do not reverse the disease [12].”
BackgroundSelf-citationRao, L., Zhu, P., Guo, M., Hu, M., Guo, X., Du, Y., & Xu, G. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102298 · Cited by 24
Highlights on Future Treatments of IPF: Clues and Pitfalls
Libra, A., Sciacca, E., Muscato, G., Sambataro, G., Spicuzza, L., & Vancheri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158392 · Cited by 25
“Some clinical trials were prematurely terminated due to failure to reach the primary endpoint [5].”
BackgroundZheng, H., Zhang, L., Wang, C., Wang, Y., & Zeng, C. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02715-2 · Cited by 34
“Tranilast (N-[3 ’ ,4 ’ - dimethoxy-cinnamoyl]-o-aminobenzoic acid), a structural analog of tryptophan metabolites, has demonstrated anti fi brotic potential.”
InfluentialBastos, V. A. F., de Souza, A. G., Guedes, V. C. S., & Cunha, T. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199476 · Cited by 27
“In the lung, meaningful regression is uncommon, and current antifibrotics are capable of only slowing functional decline with limited reversal of established scar [104].”
Holistic management of patients with progressive pulmonary fibrosis
Oliveira, A., Fabbri, G., Gille, T., Bargagli, E., Duchemann, B., Evans, R. A., Pinnock, H., Holland, A. E., Renzoni, E. A., Ekström, M. P., et al. (2023) · Breathe · doi:10.1183/20734735.0101-2023 · Cited by 26
“Breathlessness is the most common and often the initial symptom experienced by patients with ILD [1, 32].”
BackgroundWang, X., Wan, W., Lü, J., & Liu, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124096 · Cited by 25
Feng, J., Liu, H., Jiang, K., Gong, X., Huang, R., Zhou, C., Mao, J., Chen, Y., Xu, H., Zhang, X., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123128 · Cited by 20
Fang, Y., Zhang, C., Han, M., Wang, Y., Zhou, T., Xing, L., Wei, N., Wang, J., Jeong, J., Zhou, F., et al. (2025) · Advanced Materials · doi:10.1002/adma.202414601 · Cited by 22
Biomechanical Properties and Cellular Responses in Pulmonary Fibrosis
He, A., He, L., Chen, T., Li, X., & Cao, C. (2024) · Bioengineering · doi:10.3390/bioengineering11080747 · Cited by 28
A deep insight into ferroptosis in lung disease: facts and perspectives
Zhang, F., Yu, X., Ma, Q., Guo, E., & Zeng, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1354859 · Cited by 23
“Pulmonary fi brosis is a lung disease in which fi broblasts proliferate, a large amount of extracellular matrix accumulates leading to scarring, accompanied by in fl ammatory cell in fi ltration and destruction of alveolar wall structure (130, 131).”
BackgroundAlbendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis
Zeng, C., Yue, H., Wang, C., Ju, X., Wang, T., Fu, X., Zhou, Q., Zhang, H., He, L., Yu, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05655-0 · Cited by 24
“Idiopathic pulmonary fibrosis (IPF) is a devastating lung disorder characterized by the gradual formation of scars within the lung tissue, leading to impaired gas exchange, respiratory failure, and high mortality rates [1].”
BackgroundLiao, Y., Peng, X., Yang, Y., Zhou, G., Chen, L., Yang, Y., Li, H., Chen, X., Guo, S., Zuo, Q., et al. (2024) · Inflammation · doi:10.1007/s10753-024-02107-1 · Cited by 19
“Advances in clinical diagnosis and the broad application of high-resolution computed tomography, among other factors such as aging, have led to an increase in IPF incidence over the past two decades, particularly among individuals older than 65 [2].”
Pan, B., Wu, F., Lu, S., et al. (2024) · Small Methods · doi:10.1002/smtd.202400980 · Cited by 18
Chen, Y., Li, M., Yang, J., Chen, Y., & Wang, J. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04490-4 · Cited by 26
“The global burden of PF is substantial and rising, with estimated incidence rates ranging from 91 to 97 per 100,000 persons and mortality rates continuing to rise by an average of 1.7% each year [2].”
InfluentialHe, M., Zhou, J., Yang, T., Li, X., & Wang, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1310286 · Cited by 21
Emerging role of BMPs/BMPR2 signaling pathway in treatment for pulmonary fibrosis
Ye, Q., Taleb, S. J., Zhao, J., & Zhao, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117178 · Cited by 22
“Honeycombing changes in lungs can be observed by computed tomography (CT) scans [4,19].”
BackgroundFlow Cytometry as an Alternative to Microscopy for the Differentiation of BAL Fluid Leukocytes
Bratke, K., Weise, M., Stoll, P., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.03.037 · Cited by 16
“BAL, originally developed as a research tool in the 1970s, 1-5 has become an essential diagnostic tool in clinical practice, primarily for the evaluation of interstitial lung diseases 6-8 and infectious diseases, 9,10 with acceptable safety.”
Wei, L., Li, G., Peng, D., Li, N., & Wang, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-50055-x · Cited by 15
“The diagnosis of IPF, a chronic progressive fibrotic lung disease, requires careful exclusion of secondary causes of pulmonary fibrosis 43 .”
BackgroundZhang, X., Xie, Y., Cai, Y., Huang, H.-T., Liang, H., Liao, G., Jiang, Y., Peng, X., Zhan, S., & Huang, X. (2024) · Food & Function · doi:10.1039/d4fo01474j · Cited by 18
Chakraborty, A., Wang, C., Hodgson‐Garms, M., Broughton, B. R. S., Frith, J. E., Kelly, K., & Samuel, C. S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117259 · Cited by 16
Lu, J., Wang, Z., & Zhang, L. (2025) · Gene · doi:10.1016/j.gene.2025.149271 · Cited by 21
Exercise and tissue fibrosis: recent advances in therapeutic potential and molecular mechanisms
Zhao, Z., Zhu, Y., & Wan, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1557797 · Cited by 25
Idiopathic pulmonary fibrosis: current diagnosis and treatment
Amaral, A. F., Colares, P. D. F. B., & Kairalla, R. A. (2023) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230085 · Cited by 32
ZIP transporters‐regulated Zn 2+ homeostasis: A novel determinant of human diseases
Liu, H., Li, L., & Lu, R. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31223 · Cited by 18
“IPF is a fatal interstitial lung disease characterized by repetitive epithelial injury and inadequate alveolar epithelial repair (Podolanczuk et al., 2023).”
BackgroundSacchi, M., Tomaselli, D., Ruggeri, M. L., Aiello, F. B., Sabella, P., Dore, S., Pinna, A., Mastropasqua, R., Nubile, M., & Agnifili, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052327 · Cited by 25
Wei, X., Jin, C., Li, D., Wang, Y., Zheng, S., Feng, Q., shi, N., Kong, W., Ma, X., & Wang, J. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.06.008 · Cited by 18
Cheng, Y., Mei, X., Shao, W., Zheng, J., Yin, X., Zhang, Q., Li, J., & Zhao, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112792 · Cited by 18
Yang, Y., Lv, M., Xu, Q., Wang, X., & Fang, Z.-J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s491335 · Cited by 15
Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis
Zhao, T., & Su, Y. (2025) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2025.10001 · Cited by 29
“There are no effective treatment options yet for IPF, because the exact mechanisms underlying pulmonary fibrosis are not fully understood [7].”
Ahmad, Y., Mooney, J. J., Allen, I. E., Seaman, J. E., Kalra, A., Muelly, M. C., & Reicher, J. J. (2024) · Diagnostics · doi:10.3390/diagnostics14080830 · Cited by 16
“IPF patients are typically diagnosed in their 60s, with incidence and prevalence varying from 1 to 13 and 3 to 45 per 100,000, respectively [3].”
BackgroundNiu, M., Wang, Y., Deng, X.-M., Wu, X., Hua, Z.-Y., & Lü, T. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117285 · Cited by 12
The Fibrotic Phenotype of Human Precision-Cut Lung Slices Is Maintained after Cryopreservation
Marimoutou, M., Patel, V., Kim, J. H., Schaible, N., Alvarez, J., Hughes, J., Obermok, M., Rodríguez, C. I., Kallarakkal, T. G., Suki, B., et al. (2024) · Toxics · doi:10.3390/toxics12090637 · Cited by 12
“Unfortunately, IPF’s prevalence is on the rise, with approximately 50,000 new cases diagnosed annually in the United States alone [7].”
BackgroundSenhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 15
Buccardi, M., Grandi, A., Ferrini, E., Buseghin, D., Villetti, G., Civelli, M., Sverzellati, N., Aliverti, A., Pennati, F., & Stellari, F. F. (2024) · Scientific Reports · doi:10.1038/s41598-024-65030-3 · Cited by 13
“Lung transplantation often remains the only option for IPF patients 4 .”
BackgroundTanshinone IIA Loaded Inhaled Polymer Nanoparticles Alleviate Established Pulmonary Fibrosis
Chen, W., Gao, Y., Liu, Y., Luo, Y., Xue, X., Xiao, C., & Wei, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00532 · Cited by 10
Zhou, H., Zheng, X., Huang, S., Wang, X., Zhou, T. J., Zhang, S., Ling, Y., Wang, W., Li, X., Li, S., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70105 · Cited by 13
Wang, Y., Zhao, Y., Cao, G., Jiang, M., Yuan, X., Li, H., Song, X., Zhang, J., Lv, C., & Zhang, S. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70639 · Cited by 17
“IPF progressively worsens dyspnea, ultimately resulting in hypoxemia and death from respiratory failure [1, 2].”
García‐Manso, I. G., Arenas-Jiménez, J. J., Blasco, L., García‐Garrigós, E., Pérez, E. N., Matilla, M. S., Ruiz‐Alcaraz, S., & Sevila, R. G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26623 · Cited by 11
“Involvement is limited to the lung, and it is correlated with the radiological and histological pattern of usual interstitial pneumonia (UIP) [1,2].”
BackgroundGuo, J., Wang, Y., Liu, Q., Luo, Z., Tian, X., Wang, Y., Liu, Y., Ning, Z., Guo, Y., Gao, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202501956 · Cited by 11
Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans
Chang, A., Ry, P. M. V., & Raghu, G. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00325-9 · Cited by 10
Self-citationSmoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis
Fang, M., He, B., & Xiao, J. Y. (2024) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntae100 · Cited by 9
Zhu, J., Liu, H., Gao, R., Gong, R., Wang, J., Zhou, D., Yu, M., & Li, Y. (2024) · Thorax · doi:10.1136/thorax-2024-221398 · Cited by 10
Xu, Q., Hu, G., Lin, Q., Wu, M., Tang, K., Zhang, Y., & Chen, F. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03198-0 · Cited by 10
Burgy, O., & Königshoff, M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183970 · Cited by 11
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00296-0 · Cited by 18
“Conversely, neither drug has shown effectiveness in relieving symptoms, and few patients experience safety and tolerability issues, mainly gastrointestinal [8, 9].”
Nie, Z.-Q., Wu, J., Xie, J., & Yin, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33314 · Cited by 8
“The condition is distinguished by persistent alveolar type II epithelial injury, myofibroblast formation and excessive deposition of extracellular matrix (ECM) in the lung parenchyma [1,2].”
BackgroundZhou, S., Cheng, W., Liu, Y., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-03011-w · Cited by 8
“Among numerous different types of PF, the most common is idiopathic pulmonary fibrosis (IPF), which seriously affects patients’ quality of life [2].”
BackgroundFatty acid synthase inhibition alleviates lung fibrosis via β-catenin signal in fibroblasts
Lian, H., Zhang, Y., Zhu, Z., Wan, R., Wang, Z., Yang, K. J., Ma, S., Wang, Y., Xu, K., Cheng, L. C., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402805 · Cited by 11
Zhu, J., Wang, Y., Liu, H., Wang, M., Wang, J., Ding, L., Zhou, D., & Li, Y. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-906oc · Cited by 9
Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis
Steele, H., Willicut, A., Dell, G., Ghastine, A., Nguyen, X.-X., Lembicz, P., Doerflein, H., Suchoski, T., Kato, E., Feghali‐Bostwick, C. A., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf002 · Cited by 7
Monteleone, G., Passantino, L., Simonetti, J., Iovene, B., Varone, F., Cameli, P., Sgalla, G., & Richeldi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145100 · Cited by 9
“These processes induce EMT, leading to fibroblast activation, which is mediated by TGF-β and other pro-fibrotic pathways, ultimately resulting in ECM deposition and fibrotic degeneration of the lung interstitium [6,28,30].”
Self-citationXiao, Y., Hoorain, I., Zhang, L., Bellusci, S., Jin, X., Yang, H., & Zhang, J.-S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1725041 · Cited by 9
“…patient strati fi cation (3); optimizing versatile loading methodologies to facilitate synergistic combination therapies with diverse therapeutic modalities (4). viable alternatives for pretreatment strategies to exhibit excellent biocompatibility and signi fi cantly potentiate regenerative outcomes.”
Luo, M., Al-waqeerah, A., & Gao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1742761 · Cited by 10
Zhu, H., Zhou, A., Zhang, M., Pan, L., Wu, X., Fu, C., Gong, L., Yang, W., Liu, D., & Cheng, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305025 · Cited by 10
Zhang, K., Yao, E., Aung, T., & Chuang, P. (2024) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2024.01.002 · Cited by 12
Zhao, A., Unterman, A., Hussein, N. S. A., Sharma, P., Flint, J., Yan, X., Adams, T. S., Justet, A., Sumida, T. S., Zhao, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558301 · Cited by 14
Lu, X. Y., Zhu, C., Gao, Y., Yu, Z., Yan, Q., Liu, Y., Luo, M., & Shi, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107018 · Cited by 8
Zhang, Y., Xia, Y., Zhang, R., Zhou, X., & Jiang, J. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.05.015 · Cited by 7
Liu, B., Liu, W., Li, H., Zhai, N., Lv, C., Song, X., & Yang, S. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05613-z · Cited by 11
“The US Food and Drug Administration has approved only two drugs, pirfenidone and nintedanib, for IPF treatment [2].”
Gao, H., Sun, Z., Hu, X., Song, W., Liu, Y., Zou, M., Zhu, M., & Cheng, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1486357 · Cited by 12
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A. G., Chianese, M. I., Nes, A. D., Maggisano, M., Galantino, A., Nicolosi, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030411 · Cited by 8
“Despite some therapeutic options, the average survival without treatment remains limited, between 3 and 5 years post-diagnosis [6,7,10].”
PINK1 deficiency alleviates bleomycin-induced pulmonary fibrosis in mice
Gu, Y., Wu, J., Wang, T., Yu, Y.-F., Han, J., Chen, Y.-L., Hu, X., Wu, M., Hu, H., Zhang, W., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111868 · Cited by 10
Paz-Gómez, D., Castillejos-López, M. D. J., Romero, Y., Flores‐Soto, E., Romero-Martínez, B. S., Vázquez-Pérez, J. A., González-Ávila, G., Ruiz, V., Carlos‐Reyes, Á., Velázquez‐Cruz, R., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115302 · Cited by 8
“…survival median of 2–3 years, and it is characterized for being progressive with a poor prognosis; patients show progressive dyspnea and an unproductive cough that produces restrictive disrepair with a decrease in carbon monoxide diffusion capacity, which leads to a declining quality of life [6,7].”
Ferroptosis in Pneumoconiosis: From Molecular and Cellular Mechanisms to Therapeutic Strategies
Yan, M., Zhang, J., Ji, G., Fang, X., & Mo, C. (2025) · Med Research · doi:10.1002/mdr2.70020 · Cited by 18
Colligiani, L., Marzi, C., Uggenti, V., Colantonio, S., Tavanti, L. M., Pistelli, F., Alì, G., Neri, E., & Romei, C. (2025) · La radiologia medica · doi:10.1007/s11547-025-02067-y · Cited by 12
“1a and b), featuring honeycombing, traction bronchi-ectasis, septal thickening, and reduced lung volumes [3].”
Li, Z., Qin, N., Ni, W., Shen, Z., Wang, Y., Shen, J., & Li, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114485 · Cited by 8
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., King, C. S., Salvo, M. D., Weigt, S. S., Pandya, S., Bandyopadhyay, D., Lasky, J. A., Krishna, R., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2501488 · Cited by 29
Fan, S., Xue, B., & Ma, J. (2024) · Medicine · doi:10.1097/md.0000000000039013 · Cited by 9
Kim, T. Y., Yeo, H., Jung, E., & Shin, S. Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150567 · Cited by 7
Wu, L., Liu, Y., Zhang, Y., Xu, R., Bi, K., Li, J., Wang, J., Liu, Y., Guo, W., Wang, Q., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76263-7 · Cited by 10
Zheng, W., Zou, M., Hu, X., Gao, H., Song, W., Hou, Q., Liu, Y., & Cheng, Z. (2025) · Communications Biology · doi:10.1038/s42003-025-07529-7 · Cited by 10
The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
Monteleone, G., Cameli, P., & Bonella, F. (2025) · European Respiratory Review · doi:10.1183/16000617.0147-2024 · Cited by 10
“A decade ago, nintedanib and pirfenidone were approved as antifibrotic treatments based on their efficacy in slowing down disease progression and prolonging survival [12].”
Tesolato, S. E., Vicente-Valor, J., Jarabo, J. R., Calatayud, J., Saiz‐Pardo, M., Nieto, A., Álvarez, D. Á., Linares, M.-J., Fraile, C.-A., Hernándo, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123257 · Cited by 8
“IPF is a progressively fibrosing ILD with the radiological and/or histological pattern of usual interstitial pneumonia (UIP), in the exclusion of environmental factors ascribed to ILD (such as domestic and occupational environmental exposures, connective tissue diseases or drug toxicity) [5,6].”
BackgroundZhai, H., Jiang, M., Zhao, Y., Wang, Y., Zhang, H., Ji, Y., Song, X., Zhang, J., Lv, C., & Li, M. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae051 · Cited by 7
Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis
Bocchi, E., Pitozzi, V., Pontis, S., Caruso, P. L., Beghi, S., Caputi, M., Trevisani, M., & Ruscitti, F. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908305 · Cited by 8
Biomarkers for Early Diagnosis of Idiopathic Pulmonary Fibrosis: A Systematic Review
Zhai, K., Zang, D., Yang, S., Zhang, Y. L., Niu, S., & Yu, X. (2024) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-024-00909-0 · Cited by 6
“…populations should be selected based on high-risk factors for IPF, including age over 50 years, male sex, smoking history exceeding 20 pack-years, and occupational or environmental exposures (such as prolonged exposure to metal and wood dust or chemicals in agricultural activities) [72, 73].”
Wang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., Zhou, L., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530697 · Cited by 17
Malnutrition, Sarcopenia, and Malnutrition Sarcopenia Syndrome in Idiopathic Pulmonary Fibrosis
Cabrera-César, E., Fernández‐Jiménez, R., López-García, J., Sánchez, A. S., Gamonoso, M. B.-C., Agüero, I. A., Espíldora-Hernández, F., García, L. F. D. R., Vega-Aguilar, I., Amaya-Campos, M. D. M., et al. (2025) · Advances in respiratory medicine · doi:10.3390/arm93030011 · Cited by 7
Metadata
- Authors
- Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G.
- Affiliations
- Weill Cornell Medicine (US)
- Mount Auburn Hospital (US)
- Università Cattolica del Sacro Cuore (IT)
- St. Joseph’s Healthcare Hamilton (CA)
- University of Washington (US)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2023-01-26
- Volume
- 61
- Issue
- 4
- Pages
- 2200957
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4318071623
- Cited by
- 359
- References
- 196
- Citations by year
- 2026: 112 · 2025: 126 · 2024: 101 · 2023: 20
- FWCI
- 65.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, lung function decline, disease progression, natural history (disease), pathobiology, genetic risk factors, comorbidities, patient monitoring, palliative care, lung transplantation, early detection, diagnosis
- MeSH terms
- Aged, Humans, Tomography, X-Ray Computed, Lung Transplantation, Disease Progression, Early Diagnosis, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.